An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects.

Inclusion Criteria Patients must have: HIV antibody seropositivity or diagnosis of AIDS. Confirmed oropharyngeal candidiasis. Failed fluconazole treatment within the past 14 days. Life expectancy of at least 3 months. NO symptoms of esophageal candidiasis (e.g., dysphagia) unless endoscopic exam of esophagus was performed and fungal esophagitis was not present. NO prior disseminated candidiasis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Underlying clinical condition that precludes study completion or places the patient at significant risk. Considered unreliable about following physician's directives. Concurrent Medication: Excluded: Investigational drugs (approved expanded access drugs are permitted). Rifampin. Rifabutin. Phenobarbital. Phenytoin. Carbamazepine. Terfenadine. Astemizole. Patients with the following prior conditions are excluded: History of hypersensitivity to imidazole or azole compounds. Clinical evidence of significant hepatic disease within the past 2 months. Prior Medication: Excluded: Investigational drugs within 1 month prior to study entry (approved expanded access drugs are permitted).